ESTRO 36 Abstract Book

600 / 1096

S584 ESTRO 36
_______________________________________________________________________________________________
Decision Aid Tool (PDA, . The
goal is help patients to understand treatment options and
support clinicians to gain perspective of patients’
preferences.
Material and Methods
The PDA was validated following the International Patient
Decision Aid Standards (IPDAS). First, a prototype was
created considering literature and input from an
interdisciplinary group. A mixed-method (interview, 5-
Likert questionnaire) was used to identify patients’
decisional needs, and to evaluate if the tool was clear and
perceived as useful for shared-decision making.
Clinicians (N=8) and patients (N= 12) from two hospitals
were included.
Results
Patients and clinicians agreed on patient’s difficulty to
recall spoken information and understand risk
probabilities. They mentioned the need of information
about treatment options, side effects, and effectiveness.
Patients asked for information about procedures before
and after treatment.
Patients preferred information that is simple, visual, and
in small chunks. Clinicians preferred information adapted
to patient’s psychosocial level.
Patients were positive about the PDA. All criteria
(satisfaction, effectiveness, clarity, usability, usefulness,
intention use) had a median (IQR) of 4 ('agree”). Patients
asked for simpler terms, information on psychological
effects and the 'no treatment option”.
Considering these results, a new version was created
(Fig.1). It is a visual tool, containing video interviews with
clinicians and animations to explain the treatments.
This version will be validated by clinicians and patients for
comprehensibility and usability. Results will be considered
to create a final version. Thereafter, we will evaluate its
impact on shared decision-making in a multi-center
setting.
Fig. 1: Web-based decision aid tool for advanced larynx
cancer patients
Conclusion
A systematic validation process, as IPDAS, makes it
possible to understand the characteristics and decisional
needs of patients and clinicians, which are specific and
differ among diseases and contexts. This is essential for
implementation of PDAs in the clinical practice.
EP-1062 Hypofractionated vs standard radical
radiotherapy in early (T1-T2) glottic cancer patients.
M.A. González Ruiz1, J.J. Cabrera Rodríguez1, A. Ruiz
Herrero1, M.C. Cruz Muñoz1, P. Simón Silva1, J. Quirós
Rivero1, J.L. Muñoz García1, Y. Ríos Kavadoy1, M.F.
Ropero Carmona1, F. García Urra1
1 Infanta Cristina Hospital, Radiation Oncology, Badajoz,
Spain
Purpose or Objective
To analyze the results [(disease free survival (DFS) and
overall survival (OS)] of patients (pts) with glottic cancer
(GC) treated with hypofractionated radiation therapy
versus standard radiotherapy treatment with radical
intention.
Material and Methods
Retrospective comparative study of 125 pts with GC T1 or
T0is stage (119 pts) and T2 stage (6 pts) treated with
radical intention with radiation therapy in our hospital
from June 1995 to June 2015. Hypofractionated treatment
(2,25 Gy/fraction; total dose 63 Gy) was used in 42 pts and
standard treatment (2 Gy/fraction; total dose 70 Gy) was
used in 83 pts. Baseline characteristic were similar in both
groups. Median total dose of radiotherapy was 66 Gy
(range 63-70). Kaplan-Meier curves have been used for the
statistical analysis of survival and the log-rank test for the
comparison of the survivals. Treatment-related toxicity
was assessed using RTOG and the NCI-Common
Terminology Criteria for Adverse Events guidelines.
Results
The median follow-up was 215 months. The DFS and OS in
hypofractionated group were 97,6% and 93% respectively
and in standard radiotherapy group were 93% and 95,2%
respectively without statistically significant differences.
When we analyzed OS by stage subgroups, we can see that
in T1 or T0is group the results are better (95,8%) than in
T2 group 66,7% (p 0,001) without differences because of
the treatment regimen used. In the analysis according to
the age of the pts, we had the following results in terms
of OS: < 70 years-old pts treated with hypofractionated
treatment (28 pts) were 96,4 % and >70 years-old pts (14
pts) were 100%. The OS in < 70 years-old pts treated with
standard treatment (43 pts) was 93% and in >70 years-old
pts (40 pts) was 92,5% without statistically significant
differences. When we analyze OS according to the anterior
commissure involvement, we haven´t found statistically
significant differences. In both groups the majority of pts
had acute skin and mucosa toxicity grade 1-2 without
statistically significant differences regardless the regimen
of treatment used.
Conclusion
Hypofractionated treatment supposed better local disease
control than standard treatment but in terms of OS there
weren´t any differences. When we analized our pts by
subgroups stage, we found that T2 stage group had worse
results than T1 or T0is stage group in terms of OS (p 0,001)
regardless of treatment used. There weren´t no
differences in terms of toxicity nor local control between
elderly pts and young pts regardless of treatment used
either.
EP-1063 Epidemiology and clinical outcome of HPV in
different head and neck cancer a subgroup analysis
E. Boelke1, B. Gössler1, B. Tamaskovic 1, W. Budach 1, C.
Matuschek1
1University Hospital Düsseldorf Heinrich Heine University
Düsseldorf, Radiation Oncology, Düsseldorf, Germany
Purpose or Objective
Human papillomavirus (HPV)-associated squamous cell
carcinoma of the oropharynx is a well-defined disease
typically affecting young to middle-aged male non-
smokers. The incidence of HPV-associated oropharyngeal
cancers is rapidly increasing in most Western countries,
but detailed epidemiological data are not available for the
Dusseldorf population. Moreover, among other head and
neck regions, a less significant proportion of oral high-
grade dysplasia and cancers appears to depend on HPV
infection, whereas its role in laryngeal cancer is
recognized as less significant. The aim of this study was to
find out the incidence and clinical outcome of HPV
infection in different head neck cancer patients in a
German population.
Material and Methods
In this retrospective study, the tumour tissue from 164
patients (110 men, 54 women, 62.8 years + 12.7) with
head neck cancer (oropharynx = 65 nasopharynx = 10,
larynx = 13, hypopharynx = 15, oral cavity = 33 CUP = 5,